biote (BTMD)
NASDAQ:BTMD
Want to see BTMD full AI Analyst Report?
BTMD Stock Chart & Stats
$2.22
-$0.14(-2.36%)
At close: 4:00 PM EST
$2.22
-$0.14(-2.36%)
Day’s Range― - ―
52-Week Range$1.27 - $4.75
Previous CloseN/A
Volume19.10K
Average Volume (3M)315.30K
Market Cap
$84.93M
Enterprise Value$203.23M
Total Cash (Recent Filing)$5.32M
Total Debt (Recent Filing)$108.42M
Price to Earnings (P/E)4.4
Beta1.47
Next Earnings
Aug 06, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.50
Shares Outstanding30,331,425
10 Day Avg. Volume335,797
30 Day Avg. Volume315,298
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.39
Price to Sales (P/S)0.42
P/FCF Ratio2.70
Enterprise Value/Market Cap2.39
Enterprise Value/Revenue1.08
Enterprise Value/Gross Profit1.58
Enterprise Value/Ebitda5.45
Forecast
1Y Price Target
$2.75Price Target Upside23.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.29
Revenue Forecast (FY)$190.80M
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And Durable Gross MarginsConsistent positive operating and free cash flow combined with high gross margins provide a durable cash cushion. This supports reinvestment in sales and supply, funds working capital needs, and reduces immediate refinancing pressure, improving resilience over the next 2–6 months.
Large Practitioner Network And Procedure ScaleA broad certified practitioner base and substantial procedure history create recurring demand and distribution leverage. Scale across clinics and patients supports cross‑selling (supplements and services), raises barriers to entry, and underpins sustainable procedure revenue over ensuing quarters.
Expanded Commercial Capacity (salesforce Growth)A larger salesforce increases capacity to onboard practitioners and drive procedure and supplement adoption. Given typical ~6‑month ramp to contribution, the expanded team is a durable revenue growth lever, improving top‑line prospects and practitioner penetration over the medium term.
Bears Say
Negative Equity And Elevated LeveragePersistent negative equity and meaningful debt materially reduce financial flexibility, increasing refinancing and covenant risk. That capital structure limits capacity for opportunistic investment or M&A, and leaves less cushion to absorb operational shocks over the coming quarters.
Flat To Down Revenue And Margin VariabilityStagnant or modestly declining revenue combined with stepped‑down profitability reduces predictability of cash flows. Margin volatility diminishes sustainable free cash generation and heightens sensitivity to cost or supply shocks, complicating mid‑term planning and deleveraging efforts.
Manufacturing Concentration And Third‑party RelianceReduced vertical production and greater third‑party sourcing raise structural supply and cost risk. Reliance on external suppliers can pressure gross margins, complicate inventory management, and make procedure availability vulnerable to partner disruptions, affecting provider relationships and revenue continuity.
biote News
BTMD FAQ
What was biote’s price range in the past 12 months?
biote lowest stock price was $1.27 and its highest was $4.75 in the past 12 months.
What is biote’s market cap?
biote’s market cap is $84.93M.
When is biote’s upcoming earnings report date?
biote’s upcoming earnings report date is Aug 06, 2026 which is in 48 days.
How were biote’s earnings last quarter?
biote released its earnings results on May 06, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.048 by $0.012.
Is biote overvalued?
According to Wall Street analysts biote’s price is currently Undervalued.
Does biote pay dividends?
biote does not currently pay dividends.
What is biote’s EPS estimate?
biote’s EPS estimate is 0.02.
How many shares outstanding does biote have?
biote has 30,331,425 shares outstanding.
What happened to biote’s price movement after its last earnings report?
biote reported an EPS of $0.06 in its last earnings report, beating expectations of $0.048. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of biote?
Currently, no hedge funds are holding shares in BTMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
biote Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.75 (23.87% Upside)
$2.75 (23.87% Upside)
Blogger Sentiment
Bullish
BTMD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 218.3K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.53%
12-Months-Change
Fundamentals
Return on Equity
-22.91%
Trailing 12-Months
Asset Growth
-27.84%
Trailing 12-Months
Company Description
biote
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
BTMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: material short-term financial impacts in Q1 driven by a voluntary product recall and associated supply constraints materially reduced revenue, margins and net income. Offsetting these headwinds were notable operational and commercial progress — strong dietary supplement growth (+19.1%), a sizable expansion of the salesforce (to ~120 reps), training of 200+ new practitioners (+16.5% YoY), active remediation at Asteria (second shift and safety stock build), and maintained full-year guidance (revenue > $190M; adjusted EBITDA > $38M). Management expressed confidence that the issues are temporary and expected a return to procedure revenue growth in the second half of 2026, but acknowledged near-term persisting effects into Q2.View all BTMD earnings summariesBTMD Stock 12 Month Forecast
Average Price Target
$2.75
▲(23.87% Upside)
Technical Analysis
Concord Medical Services
―
Joint
―
Cryo-Cell International
―
DocGo
―
P3 Health Partners
―
Ownership Overview
9.01% Insiders
9.62% Mutual Funds
24.78% Other Institutional Investors
48.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---